Sage Therapeutics, Inc. (SAGE) and Biogen Inc. (BIIB) Wednesday said the Phase 2 KINETIC 2 study evaluating SAGE-324 to treat essential tremor (ET) did not meet primary goal.
Essential tremor is a neurological condition, that causes involuntary shaking of body parts.
The study did not demonstrate a statistically significant dose-response relationship in change from baseline to Day 91 based on the primary endpoint The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale (PS) Item 4 (upper limb) total score, in participants with ET.
The companies plan to close the ongoing safety study of SAGE-324 in ET, and do intend to do any further studies of SAGE-324 in ET.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.